Rigel Pharmaceuticals Inc
RIGL· Nasdaq
RIGLRigel Pharmaceuticals Inc
Released Aug 1, 2023, after the close
10-Q filed Aug 1, 2023, 32 days after period end · 0001558370-23-012722
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $26.89M | $29.82M | $26.27M | $16.02M |
| Net Income | -$6.60M | -$13.49M | -$13.82M | -$17.58M |
| EPS Diluted |
Rigel Pharmaceuticals Inc · CIK 1034842 · Engraved from SEC EDGAR
| -$0.38 |
| -$0.08 |
| -$0.08 |
| -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
